Editorials
Vol. 1 No. 1 (2022)
The night of randomized clinical trials where all patients are black: a need to estimate variability in treatment effects
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 22 March 2022
1797
Views
262
Downloads
Authors
In the Sixties, the few anti-thrombotic drugs available were administered following several criteria including tradition of the “School”, preference of the doctor in charge, pressure of pharmaceutical companies [...]
Downloads
Download data is not yet available.
Citations
Peto R. Aspirin after myocardial infarction. Lancet 1980;1:1172-3. DOI: https://doi.org/10.1016/S0140-6736(80)91626-8
Antithrombotic Trialists' Collaboration. Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86. Erratum in: BMJ 2002;324:141. DOI: https://doi.org/10.1136/bmj.324.7329.71
Sackett DL, Rosenberg WM, Gray JA, et al. Evidence based medicine: what it is and what it isn't. BMJ 1996;312:71-2. DOI: https://doi.org/10.1136/bmj.312.7023.71
Liberati A. Need to realign patient-oriented and commercial and academic research. Lancet 2011; 378: 1777-8. DOI: https://doi.org/10.1016/S0140-6736(11)61772-8
de Gaetano G, Cerletti C, Dejana E, Vermylen J. Current issues in thrombosis prevention with antiplatelet drugs. Drugs 1986;31:517-49. DOI: https://doi.org/10.2165/00003495-198631060-00004
Roses AD. Pharmacogenetics and the practice of medicine. Nature 2000;405(6788):857-65. DOI: https://doi.org/10.1038/35015728
Liuzzo G, Patrono C. Give genotype-guided dual antiplatelet therapy a second CHANCE. Eur Heart J 2022;43:938-9. DOI: https://doi.org/10.1093/eurheartj/ehac024
Angus DC, Chang CH. Heterogeneity of treatment effect: estimating how the effects of Interventions vary across individuals. JAMA 2021;326:2312-3. DOI: https://doi.org/10.1001/jama.2021.20552
Athey S, Imbens G. Recursive partitioning for heterogeneous causal effects. Proc Natl Acad Sci U S A 2016;113: 7353-60. DOI: https://doi.org/10.1073/pnas.1510489113
Di Castelnuovo A, Gialluisi A, Antinori A, et al. Disentangling the association of hydroxychloroquine treatment with mortality in Covid-19 hospitalized patients through Hierarchical Clustering. J Healthc Eng 2021;2021:5556207. DOI: https://doi.org/10.1155/2021/5556207
How to Cite
1.
de Gaetano G, Cerletti C, Iacoviello L, Donati MB. The night of randomized clinical trials where all patients are black: a need to estimate variability in treatment effects. Bleeding Thromb Vascul Biol [Internet]. 2022 Mar. 22 [cited 2025 Sep. 6];1(1). Available from: https://www.btvb.org/btvb/article/view/24
Copyright (c) 2022 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Similar Articles
- Paolo Gresele, Artificial intelligence and machine learning in hemostasis and thrombosis , Bleeding, Thrombosis and Vascular Biology: Vol. 2 No. 4 (2023)
- Pier Mannuccio Mannucci, An ecological alliance against air pollution and cardiovascular disease , Bleeding, Thrombosis and Vascular Biology: Vol. 1 No. 1 (2022)
- Massimo Franchini, Polycythemia vera and management of the thrombotic risk: an update , Bleeding, Thrombosis and Vascular Biology: Vol. 2 No. 4 (2023)
- Mehrie H. Patel, Alok A. Khorana, New drugs, old problems: immune checkpoint inhibitors and cancer-associated thrombosis , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. s1 (2024)
- Licia Iacoviello, Maria Benedetta Donati, Unveiling the “common soil” of cardiovascular disease and cancer , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. 1 (2025)
- Alessandro Pezzini, The balance between hemorrhage and thrombosis in patients surviving spontaneous intracerebral bleeding: the nightmare of a neurologist , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. 2 (2024)
- Gianfranco De Girolamo, Luca Sarti, Sonia Cecoli, Karin Bonora, Chiara Ajolfi, Francesco Bellelli, Valeria Coluccio, Gualtiero Palareti, Marco Marietta, Safety and efficacy of treatment with vitamin K antagonists in patients managed in a network of anticoagulation services or as routine general care , Bleeding, Thrombosis and Vascular Biology: Vol. 1 No. 1 (2022)
- Luca Puccetti, Vincenzo Sammartano, Federico Caroni, Margherita Malchiodi, Paola Calzoni, Eleonora Franceschini, Lucrezia Galasso, Monica Bocchia, Safety of COVID-19 mRNA vaccination in patients with history of acquired hemophilia A: a case series , Bleeding, Thrombosis and Vascular Biology: Vol. 1 No. 3 (2022)
- Robert Parambi, Nicole Ziliotto, Francesco Bernardi , Marcello Baroni , Richard W Browne , Dejan Jakimovski, Bianca Weinstock-Guttman, Robert Zivadinov, Murali Ramanathan, Crosstalk between hemostasis inhibitors and cholesterol biomarkers in multiple sclerosis , Bleeding, Thrombosis and Vascular Biology: Vol. 1 No. 3 (2022)
- Ronda Lun, Deborah M. Siegal, Cancer-associated ischemic stroke: current knowledge and future directions , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. s1 (2024)
You may also start an advanced similarity search for this article.
